Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence

Tirzepatide is associated with a 58% reduction in the risk of major adverse cardiovascular events compared to liraglutide in patients with obstructive sleep apnea and type 2 diabetes.

• Tirzepatide also shows a reduced risk of major adverse cardiovascular events compared to semaglutide, with a hazard ratio of 0.86.
• The analysis involved 7,836 patients treated with tirzepatide and corresponding reference arms of liraglutide and semaglutide.
• Tirzepatide demonstrated greater efficacy in younger, male patients of White ethnicity.
• There was a reduction in the incidence of obstructive sleep apnea among patients treated with tirzepatide compared to liraglutide.
• No significant difference in obstructive sleep apnea incidence was observed between tirzepatide and semaglutide.

AI simplified